# Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer

> **NCT04776590** · PHASE2 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 30 (estimated)

## Conditions studied

- Esophagus Cancer
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT04776590
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-28
- **Primary completion:** 2023-03-11
- **Final completion:** 2024-12-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776590, "Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04776590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*